The SAPHNELO Co-pay Savings Program helps assist eligible, commercially insured patients with out-of-pocket costs.
Learn More
AZ&Me Prescription Savings Program provides AstraZeneca medicines at no cost to qualifying patients.
Learn MoreAssistance may be available through independent foundations such as those listed below. Foundations can provide a variety of assistance types: patient savings, transportation, premium, patient education, etc.
Learn MoreSAPHNELO Supports is a patient support program created to help answer the questions your patient might have as they get started with their treatment. Access 360 is a part of SAPHNELO Supports and can help you find information about coverage, costs, and affordability programs.
We can answer their questions about:
One MedImmune Way, Gaithersburg, MD 20878
A Co-pay Savings Program account will be created for the eligible patient. This can be done by the pharmacy/practice or by calling an Access 360 representative. Once enrolled, the patient will continue to pay a set amount of his or her out-of-pocket costs for SAPHNELO. The pharmacy/practice will use the Co-pay Savings Program to cover the balance, up to the program maximum.
The patient may pay as little as $0 per administration; program pays remaining out-of-pocket costs up to a maximum of $16,500 per year. The out-of-pocket costs covered by the program can include the cost of the product itself and/or the cost of infusion of the product (program maximum of $150 per infusion administration). Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.
The SAPHNELO Co-pay Savings Program covers the cost of the drug and administration but does not cover costs for office visits or any other associated costs.
No. There are no income requirements to participate in the program.
For additional information, please visit www.astrazenecaspecialtysavings.com or call an Access 360 representative at 1-866-SAPHNELO (1-866-727-4635).
The SAPHNELO® (anifrolumab-fnia) injection for Intravenous infusion, 300 mg Savings Program is for commercially insured patients to cover patient out-of-pocket costs for SAPHNELO and its infusion administration up to $16,500 per calendar year. Patients with commercial insurance where the health plan does NOT cover SAPHNELO may qualify for the Denied Co-pay Savings Program. Subject to eligibility and terms of use.
Patients must have commercial health insurance and a valid prescription for SAPHNELO. Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. Patients who are enrolled in a state or federally funded prescription insurance program may not use this program even if they elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico. Patients who are residents of Massachusetts or Rhode Island are not eligible for infusion administration assistance.
Other restrictions may apply. Patient must be enrolled in the program before use. See full Eligibility and Terms of Use at www.SAPHNELO.com or call Access 360 at 1-866-SAPHNELO (1-866-727-4635), Monday–Friday, 8 AM to 6 PM ET, excluding holidays.
Eligibility rules apply—please call an AZ&Me representative for more information at 1-800-AZandMe (1-800-292-6363).
These foundations are not associated with AstraZeneca; specific details and eligibility requirements can be found directly at the foundations’ websites.
Find a foundationFor more information and additional resources, visit: https://www.astrazeneca-us.com/medicines/Affordability.html or call an Access 360 representative at 1-866-SAPHNELO (1-866-727-4635).
